Neurotech Pharmaceuticals announced its Encelto (revakinagene taroretcel-lwey) implant has become the first US Food and Drug Administration (FDA)-approved therapy to slow macular telangiectasia (MacTe
Prof Helen Danesh-Meyer CNZM is the first New Zealander to be appointed president of the Neuro-Ophthalmology Society of Australia (NOSA).
An international team led by New Zealand researchers found patients with type-1 diabetes had stable or improved diabetic retinopathy (DR) after using automated insulin delivery (AID) for at least six months.
New Zealand distributor Toomac Ophthalmic confirms Bausch + Lomb’s 27 March 2025 voluntary recall only concerns the enVista Envy intraocular lens (IOL) in this market.
A University of Sydney literature review found topical cyclosporine (CsA) treatment may be superior to the vehicle, artificial tears (AT) or other topical treatment alternatives for ocular surface dis
US researchers who found vascular endothelial growth factor (VEGF) played a critical role in melanoma cells metastasising to organs outside the eye are trialling a new drug to prevent it. Using an o
Medsafe hasn’t yet received an application for the approval of geographic atrophy (GA) treatment Syfovre in New Zealand, despite its recent approval in Australia. In two studies published in 2023, i
A new study¹ published in The Ocular Surface journal has found a strong need for individualised treatment strategies for patients suffering from dry eye disease (DED). Using real-world data from the
Eye Institute recently celebrated three decades of practice, with doctors and staff gathering to mark its 30th birthday with cake, speeches and a look back at the innovations and successes over the ye
United by a shared passion for eye health and advocacy, four EyesForGood volunteers set out to bring essential eyecare services to Tongan communities.
Visually impaired adventurer Neelu Jennings and Optimed’s Craig Norman are teaming up in April to race the Porirua Grand Traverse.
Kiwi-designed PhotonUVC device heads to human trials